Angle PLC Announces HER2 Presentation at SABCS
ANGLE plc announced the presentation of an independent study by Weill Cornell Medicine at the San Antonio Breast Cancer Symposium, showcasing a novel Parsortix-based HER2 workflow. The study, involving 16 metastatic breast cancer patients, demonstrated 100% success in isolating CTCs and classifying their HER2 status. The research identified patients with HER2-expressing CTCs who had HER2-negative tissue biopsies, suggesting potential for expanded treatment options.
The workflow enables quantitative and semi-automated assessment of HER2 in CTCs, which is important as HER2 status can change in up to 38% of breast cancer patients. This development could help identify patients eligible for HER2-targeted antibody drug conjugates (ADCs), particularly beneficial for the over 60% of breast cancer patients initially diagnosed as HER2-negative.
ANGLE plc ha annunciato la presentazione di uno studio indipendente condotto da Weill Cornell Medicine al San Antonio Breast Cancer Symposium, evidenziando un nuovo flusso di lavoro HER2 basato su Parsortix. Lo studio, che ha coinvolto 16 pazienti con cancro al seno metastatico, ha dimostrato un successo del 100% nell'isolamento delle CTC e nella classificazione del loro stato HER2. La ricerca ha identificato pazienti con CTC che esprimono HER2 ma con biopsie tissutali HER2-negative, suggerendo un potenziale per ampliare le opzioni di trattamento.
Il flusso di lavoro consente una valutazione quantitativa e semi-automatizzata di HER2 nelle CTC, un aspetto importante poiché lo stato HER2 può cambiare in fino al 38% dei pazienti con cancro al seno. Questo sviluppo potrebbe aiutare a identificare i pazienti idonei per i coniugati anticorpali con farmaci mirati HER2 (ADC), particolarmente vantaggioso per oltre il 60% dei pazienti con cancro al seno inizialmente diagnosticati come HER2-negativi.
ANGLE plc anunció la presentación de un estudio independiente realizado por Weill Cornell Medicine en el Simposio de Cáncer de Mama de San Antonio, que destaca un nuevo flujo de trabajo HER2 basado en Parsortix. El estudio, que involucró a 16 pacientes con cáncer de mama metastásico, demostró un éxito del 100% en el aislamiento de CTC y en la clasificación de su estado HER2. La investigación identificó pacientes con CTC que expresan HER2 que tenían biopsias de tejido HER2-negativas, lo que sugiere un potencial para ampliar las opciones de tratamiento.
El flujo de trabajo permite una evaluación cuantitativa y semi-automatizada de HER2 en CTC, lo cual es importante ya que el estado HER2 puede cambiar en hasta el 38% de los pacientes con cáncer de mama. Este desarrollo podría ayudar a identificar pacientes elegibles para conjugados de fármacos anticuerpos dirigidos a HER2 (ADC), particularmente beneficioso para más del 60% de los pacientes con cáncer de mama diagnosticados inicialmente como HER2-negativos.
ANGLE plc는 Weill Cornell Medicine이 샌안토니오 유방암 심포지엄에서 발표한 독립 연구를 발표했다고 알림니다. 이 연구는 Parsortix 기반의 새로운 HER2 작업 흐름을 선보였습니다. 16명의 전이성 유방암 환자를 포함한 이 연구는 CTC를 분리하고 HER2 상태를 분류하는 데 100%의 성공률을 입증했습니다. 연구를 통해 HER2 양성 CTC를 가진 환자와 HER2 음성 조직 생검을 가진 환자가 확인되었습니다, 이는 치료 옵션을 확장할 수 있는 가능성을 시사합니다.
이 작업 흐름은 CTC 내 HER2의 정량적 및 반자동 평가를 가능하게 하며, HER2 상태는 유방암 환자의 최대 38%에서 변할 수 있으므로 중요합니다. 이 개발은 특히 처음에 HER2 음성으로 진단된 60% 이상의 유방암 환자에게 HER2 표적 항체 약물 결합체 (ADC)에 적합한 환자를 식별하는 데 도움이 될 수 있습니다.
ANGLE plc a annoncé la présentation d'une étude indépendante réalisée par Weill Cornell Medicine lors du San Antonio Breast Cancer Symposium, mettant en avant un nouveau flux de travail HER2 basé sur Parsortix. L'étude, impliquant 16 patients atteints de cancer du sein métastatique, a démontré un taux de succès de 100 % dans l'isolement des CTC et la classification de leur statut HER2. La recherche a identifié des patients avec des CTC exprimant HER2 qui avaient des biopsies tissulaires HER2-négatives, suggérant un potentiel d'élargissement des options de traitement.
Le flux de travail permet une évaluation quantitative et semi-automatisée de HER2 dans les CTC, ce qui est important car le statut HER2 peut changer chez jusqu'à 38 % des patientes atteintes de cancer du sein. Ce développement pourrait aider à identifier les patientes éligibles pour des conjugués thérapeutiques anticorps dirigés contre HER2 (ADC), particulièrement bénéfique pour plus de 60 % des patientes atteintes de cancer du sein initialement diagnostiquées comme HER2-négatives.
ANGLE plc gab die Präsentation einer unabhängigen Studie von Weill Cornell Medicine auf dem San Antonio Breast Cancer Symposium bekannt, die einen neuen auf Parsortix basierenden HER2-Arbeitsablauf vorstellt. Die Studie, die 16 Patienten mit metastasiertem Brustkrebs einbezog, zeigte eine 100%ige Erfolgsquote beim Isolieren von CTCs und der Klassifizierung ihres HER2-Status. Die Forschung identifizierte Patienten mit HER2-exprimierenden CTCs, die HER2-negative Gewebebiopsien hatten, was auf ein Potenzial für erweiterte Behandlungsoptionen hinweist.
Der Arbeitsablauf ermöglicht eine quantitative und halbautomatisierte Bewertung von HER2 in CTCs, was wichtig ist, da sich der HER2-Status bei bis zu 38% der Brustkrebspatienten ändern kann. Diese Entwicklung könnte helfen, Patienten zu identifizieren, die für HER2-targetierte Antikörper-Wirkstoff-Konjugate (ADCs) in Frage kommen, was insbesondere vorteilhaft für über 60% der anfangs als HER2-negativ diagnostizierten Brustkrebspatienten sein könnte.
- 100% success rate in CTC isolation and HER2 classification in study patients
- Potential to identify additional patients eligible for HER2 targeted treatments
- Semi-automated solution that could accelerate adoption of CTC-based HER2 tests
- Independent validation of ANGLE's HER2 assay development programme
- None.
WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM
Independent findings support ANGLE's HER2 assay development programme
Potential for stratification of breast cancer patients for treatment with HER2 antibody drug conjugates
SURREY, UK / ACCESSWIRE / December 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of an independent study, reporting on a novel, Parsortix®-based human epidermal growth factor receptor 2 (HER2) workflow at the prominent San Antonio Breast Cancer Symposium being held from 10 to 13 December 2024.
The findings, published by Weill Cornell Medicine, corroborate ANGLE's own findings from its HER2 assay development programme, and provide a semi-automated solution which may help to accelerate adoption of CTC-based HER2 tests. HER2 status is known to change in a significant proportion of breast cancer patients over time, so a minimally invasive, real-time assay is needed for dynamic HER2 assessment to enable targeted treatment selection and detection of emerging treatment resistance or progression.
HER2 is a protein that is associated with many cancers, and HER2 tumour marker testing is used to determine if targeted therapy will be effective. A quantitative HER2 test, that objectively measures HER2 expression levels, enables the identification of patients who are HER2-high, intermediate or low and therefore suitable for treatment with HER2-antibody drug conjugates (ADCs).
The poster reports on a study in 16 patients with metastatic breast cancer, in which the Parsortix system was used to isolate and harvest CTCs and CTC-clusters prior to automated imaging and classification as HER2-high, intermediate, low or negative. Using the Parsortix system, CTCs were identified in
Over
Dr. Carolina Reduzzi, Assistant Professor of Cancer Biology Research in Medicine, Weill Cornell Medicine commented:
"We are pleased to present further data validating our workflow which enables quantitative and semi-automated assessment of HER2 in CTCs. HER2 is a major therapeutic target and an accurate and real-time assessment of HER2 status could be used to monitor CTCs over time to better guide treatment and identify patients with any detectable HER2 expression, or changes to HER2 expression, who could benefit from treatment with ADCs.
This methodology has the potential to be applied to a wide range of biomarkers and our ultimate goal is to develop automated workflows which enable longitudinal CTC assessment of biomarker status for targeted treatment selection or to predict treatment response."
ANGLE's Chief Scientific Officer, Karen Miller, commented:
"We are pleased to see new data that supports the utility of quantitative HER2 assessment on CTCs isolated using the Parsortix system and independently validates ANGLE's own findings from our HER2 assay development programme. HER2 status is known to change in up to
The poster is available at: https://angleplc.com/resources/posters/
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive |
|
|
|
|
|
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
All results reported in this announcement and any other products and services are for research use only and not for use in diagnostic procedures.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on accesswire.com
FAQ
What were the key findings of ANPCY's HER2 Parsortix study at SABCS 2024?
How could ANPCY's Parsortix HER2 workflow benefit breast cancer patients?
What percentage of breast cancer patients could benefit from ANPCY's HER2 testing?
How does ANPCY's Parsortix system assess HER2 status in cancer patients?
